The optimum duration of front-line chemotherapy

[...]in the era of genome analysis, all modern studies should take into account the diversity of the histological subtype of non-small-cell lung cancer and the effect of pharmacogenomics in treatment decision-making.5 The failure of extended treatment to significantly improve overall survival is con...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2014-10, Vol.15 (11), p.1187-1188
Main Authors: Kotsakis, Athanasios, Georgoulias, Vassilis
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Disease control
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung cancer
Lung Neoplasms - drug therapy
Male
Meta-analysis
Patients
Pharmaceutical industry
Quality of life
Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]in the era of genome analysis, all modern studies should take into account the diversity of the histological subtype of non-small-cell lung cancer and the effect of pharmacogenomics in treatment decision-making.5 The failure of extended treatment to significantly improve overall survival is consistent with the results from studies investigating the role of maintenance treatment in patients with non-small-cell lung cancer who achieve disease control with first-line chemotherapy.6,7 However, the ideal endpoint of trials testing the efficacy of a particular regimen in the first-line setting is debated extensively.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(14)70434-6